KRAS and lung adenocarcinoma: In this report, we describe a patient with advanced primary lung adenocarcinoma harboring a KRAS G12C mutation and high PD-L1 expression (TPS ≥50%) who underwent palliative brain radiotherapy followed by PD-1 antibody therapy.